NYSE:NUVB Nuvation Bio (NUVB) Stock Price, News & Analysis → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Free NUVB Stock Alerts $4.09 +0.12 (+3.02%) (As of 10:15 AM ET) Add Compare Share Share Today's Range$3.82▼$4.1150-Day Range$1.46▼$3.9652-Week Range$0.95▼$4.11Volume1.98 million shsAverage Volume1.08 million shsMarket Capitalization$891.81 millionP/E RatioN/ADividend YieldN/APrice Target$6.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Nuvation Bio alerts: Email Address Nuvation Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside57.8% Upside$6.25 Price TargetShort InterestHealthy1.97% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.61Based on 18 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.36) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.75 out of 5 starsMedical Sector447th out of 939 stocksPharmaceutical Preparations Industry213th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingNuvation Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.25, Nuvation Bio has a forecasted upside of 57.8% from its current price of $3.96.Amount of Analyst CoverageNuvation Bio has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.97% of the float of Nuvation Bio has been sold short.Short Interest Ratio / Days to CoverNuvation Bio has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nuvation Bio has recently increased by 6.42%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNuvation Bio does not currently pay a dividend.Dividend GrowthNuvation Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NUVB. Previous Next 3.1 News and Social Media Coverage News SentimentNuvation Bio has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Nuvation Bio this week, compared to 1 article on an average week.Search Interest18 people have searched for NUVB on MarketBeat in the last 30 days. This is an increase of 1,700% compared to the previous 30 days.MarketBeat Follows15 people have added Nuvation Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 650% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nuvation Bio insiders have not sold or bought any company stock.Percentage Held by Insiders36.09% of the stock of Nuvation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.67% of the stock of Nuvation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nuvation Bio are expected to decrease in the coming year, from ($0.36) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvation Bio is -11.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvation Bio is -11.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvation Bio has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About Nuvation Bio Stock (NYSE:NUVB)Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Read More NUVB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NUVB Stock News HeadlinesMarch 28, 2024 | businesswire.comNuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial OfficerMarch 28, 2024 | americanbankingnews.comNuvation Bio (NYSE:NUVB) Reaches New 1-Year High at $2.65March 28, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)March 28, 2024 | americanbankingnews.comNuvation Bio (NYSE:NUVB) Upgraded to Buy by Jefferies Financial GroupMarch 27, 2024 | msn.comBTIG upgrades Nuvation to buy, cites AnHeart acquisitionMarch 27, 2024 | msn.comNuvation Bio continues to surge as more upgrades follow after AnHeart dealMarch 27, 2024 | americanbankingnews.comNuvation Bio Inc. (NYSE:NUVB) to Post Q1 2025 Earnings of ($0.10) Per Share, Wedbush ForecastsMarch 27, 2024 | americanbankingnews.comNuvation Bio (NYSE:NUVB) Upgraded by BTIG Research to "Buy"March 28, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)March 24, 2024 | americanbankingnews.comNuvation Bio (NYSE:NUVB) Trading 5.1% Higher March 20, 2024 | finance.yahoo.comNUVB Apr 2024 2.000 putMarch 16, 2024 | finance.yahoo.comNUVB Apr 2024 0.500 callMarch 15, 2024 | msn.comNuvation Bio begins subject dosing in Phase I/II solid tumour trialMarch 14, 2024 | businesswire.comNuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid TumorsMarch 14, 2024 | baystreet.caBiotech Sector Advances in Pancreatic Cancer ResearchMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Nuvation Bio Amid Strong Financial Performance and Promising Clinical ProgressFebruary 29, 2024 | finance.yahoo.comNuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 29, 2024 | businesswire.comNuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 17, 2024 | finance.yahoo.comOwning 46% shares,institutional owners seem interested in Nuvation Bio Inc. (NYSE:NUVB),January 8, 2024 | msn.comFDA clears Nuvation to begin Phase 1/2 study for oncology drugJanuary 8, 2024 | finance.yahoo.comNuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid TumorsJanuary 8, 2024 | finance.yahoo.comNuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of DirectorsNovember 13, 2023 | finance.yahoo.comNuvation Bio Announces Departure of Chief Financial OfficerNovember 4, 2023 | benzinga.comNuvation Bio Stock (NYSE:NUVB) Earnings Dates and Earning CallsNovember 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Nuvation Bio (NUVB) and Generation Bio (GBIO)November 3, 2023 | msn.comNuvation Bio GAAP EPS of -$0.09 beats by $0.02November 2, 2023 | finance.yahoo.comNuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business UpdateSee More Headlines Receive NUVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:NUVB CUSIPN/A CIK1811063 Webwww.nuvationbio.com Phone332-208-6102FaxN/AEmployees51Year FoundedN/APrice Target and Rating Average Stock Price Target$6.25 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+57.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-12.21% Return on Assets-11.89% Debt Debt-to-Equity RatioN/A Current Ratio44.11 Quick Ratio44.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.76 per share Price / Book1.43Miscellaneous Outstanding Shares218,050,000Free Float139,353,000Market Cap$863.48 million OptionableOptionable Beta1.19 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. David T. Hung M.D. (Age 66)Founder, President, CEO & Director Comp: $944.51kDr. David C. Hanley Ph.D. (Age 54)Chief Technical Operations Officer Comp: $586.04kMr. Moses Makunje (Age 45)Principal Accounting Officer & Principal Financial Officer Dr. Gary Hattersley Ph.D. (Age 57)Chief Scientific Officer Comp: $687.88kMs. Stacy Markel (Age 59)Chief People Officer Ms. Kerry A. Wentworth (Age 51)Chief Regulatory Officer Dr. David Liu M.D. (Age 54)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsCalliditas Therapeutics AB (publ)NASDAQ:CALTNeurogeneNASDAQ:NGNEMineralys TherapeuticsNASDAQ:MLYSSilence TherapeuticsNASDAQ:SLNAcelyrinNASDAQ:SLRNView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 18,457 shares on 3/11/2024Ownership: 3.355%Goldman Sachs Group Inc.Bought 381,555 shares on 3/1/2024Ownership: 0.363%Price T Rowe Associates Inc. MDSold 584,073 shares on 2/16/2024Ownership: 0.095%GSA Capital Partners LLPSold 187,519 shares on 2/16/2024Ownership: 0.020%Citadel Advisors LLCBought 200 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions NUVB Stock Analysis - Frequently Asked Questions Should I buy or sell Nuvation Bio stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvation Bio in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NUVB shares. View NUVB analyst ratings or view top-rated stocks. What is Nuvation Bio's stock price target for 2024? 4 Wall Street analysts have issued 1 year target prices for Nuvation Bio's shares. Their NUVB share price targets range from $5.00 to $10.00. On average, they anticipate the company's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 57.8% from the stock's current price. View analysts price targets for NUVB or view top-rated stocks among Wall Street analysts. How have NUVB shares performed in 2024? Nuvation Bio's stock was trading at $1.51 at the start of the year. Since then, NUVB stock has increased by 162.3% and is now trading at $3.96. View the best growth stocks for 2024 here. When is Nuvation Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our NUVB earnings forecast. How were Nuvation Bio's earnings last quarter? Nuvation Bio Inc. (NYSE:NUVB) released its quarterly earnings data on Thursday, February, 29th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.04. What ETF holds Nuvation Bio's stock? Range Cancer Therapeutics ETF holds 70,984 shares of NUVB stock, representing 1.25% of its portfolio. Who are Nuvation Bio's major shareholders? Nuvation Bio's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.34%), Vanguard Group Inc. (3.35%), Northern Trust Corp (0.56%), Charles Schwab Investment Management Inc. (0.51%), Octagon Capital Advisors LP (0.46%) and Goldman Sachs Group Inc. (0.36%). Insiders that own company stock include Fund V LP Omega, Kathryn E Falberg and Oleg Nodelman. View institutional ownership trends. How do I buy shares of Nuvation Bio? Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NUVB) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryUrgent: Protect Your Investments from a Chinese InvasionBehind the MarketsSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.